{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T01:17:56Z","timestamp":1782782276943,"version":"3.54.5"},"reference-count":29,"publisher":"The Endocrine Society","issue":"7","license":[{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013003","name":"University of Cagliari","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013003","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>This observational investigation aimed to assess the accuracy of a novel score in predicting the onset of overt Graves' orbitopathy (GO) in patients with Graves' disease (GD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>A total of 156 consecutive patients with GD without GO were enrolled. As control group, 45 patients with non-autoimmune hyperthyroidism were included. At baseline, an ophthalmological evaluation was performed, including (1) visual function tests and (2) orbital ultrasound. After 24 months, the occurrence of GO was assessed in all patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At baseline, a score from 0 to 3 and a score from 0 to 5 were assigned based on the results of visual function tests and the results of orbital ultrasound, respectively. The scores were combined into an overall FUnctional and MOrphological risk score (FUMO score) (0-8 points), classifying patients as low risk (score 0-2) or medium-high risk (score 3-8). After 24 months, the 2 risk groups were compared for differences in (1) presence\/absence of GO and (2) GO activity and severity. Patients in the medium-high risk group developed overt GO more frequently than those in the low-risk group. Additionally, GO was more frequently active and moderate-to-severe in medium-high risk patients. Multiple logistic regression showed that TRAb levels and FUMO were the strongest independent predictors of GO, with higher FT3 and smoking habit levels also conferring increased risk. The model demonstrated good calibration and discrimination (AUC = 0.84; P &amp;lt; .0001), with high positive (73%) and negative (72%) predictive value.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Subclinical ocular alterations can predict the progression of GO in patients with GD. The FUMO score, particularly when combined with TRAb and FT3 levels, reliably identifies patients at risk of developing overt GO, supporting its use for early risk stratification.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgag037","type":"journal-article","created":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T12:41:04Z","timestamp":1769863264000},"page":"e1863-e1873","source":"Crossref","is-referenced-by-count":1,"title":["Subclinical ocular alterations in Graves' disease: The FUMO score, a new tool to predict Graves' orbitopathy progression"],"prefix":"10.1210","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9933-4040","authenticated-orcid":false,"given":"Giulia","family":"Lanzolla","sequence":"first","affiliation":[{"name":"Department of Medical Sciences and Public Health, Endocrinology Unit, University of Cagliari and University Hospital of Cagliari , Cagliari 09100 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Saba","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences and Public Health, Endocrinology Unit, University of Cagliari and University Hospital of Cagliari , Cagliari 09100 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Corrias","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences and Public Health, Endocrinology Unit, University of Cagliari and University Hospital of Cagliari , Cagliari 09100 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Lixi","sequence":"additional","affiliation":[{"name":"Eye Clinic, Department of Surgical Sciences, University of Cagliari , Cagliari 09124 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Faa","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences and Public Health, Endocrinology Unit, University of Cagliari and University Hospital of Cagliari , Cagliari 09100 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Colleo","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences and Public Health, Endocrinology Unit, University of Cagliari and University Hospital of Cagliari , Cagliari 09100 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Mura","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences and Public Health, Endocrinology Unit, University of Cagliari and University Hospital of Cagliari , Cagliari 09100 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Luigi","family":"Canu","sequence":"additional","affiliation":[{"name":"Department of Surgical Sciences, Surgery Unit, University of Cagliari and University Hospital of Cagliari , Cagliari 09100 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Cappellacci","sequence":"additional","affiliation":[{"name":"Department of Surgical Sciences, Surgery Unit, University of Cagliari and University Hospital of Cagliari , Cagliari 09100 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Cuccu","sequence":"additional","affiliation":[{"name":"Eye Clinic, University Hospital of Cagliari , Cagliari 09124 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Giannaccare","sequence":"additional","affiliation":[{"name":"Eye Clinic, Department of Surgical Sciences, University of Cagliari , Cagliari 09124 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Mariotti","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences and Public Health, Endocrinology Unit, University of Cagliari and University Hospital of Cagliari , Cagliari 09100 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Boi","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences and Public Health, Endocrinology Unit, University of Cagliari and University Hospital of Cagliari , Cagliari 09100 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2026,2,2]]},"reference":[{"issue":"10","key":"2026061619565718100_dgag037-B1","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1055\/s-0035-1555762","article-title":"Current insights into the pathogenesis of Graves\u2019 ophthalmopathy","volume":"47","author":"Bahn","year":"2015","journal-title":"Horm Metab Res"},{"issue":"11","key":"2026061619565718100_dgag037-B2","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/s41574-024-01016-5","article-title":"Graves disease: latest understanding of pathogenesis and treatment options","volume":"20","author":"Lanzolla","year":"2024","journal-title":"Nat Rev Endocrinol"},{"issue":"4","key":"2026061619565718100_dgag037-B3","doi-asserted-by":"crossref","first-page":"G43","DOI":"10.1530\/EJE-21-0479","article-title":"The 2021 European Group on Graves\u2019 orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves\u2019 orbitopathy","volume":"185","author":"Bartalena","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2026061619565718100_dgag037-B4","doi-asserted-by":"crossref","first-page":"500","DOI":"10.3390\/medicina61030500","article-title":"Graves\u2019 disease: is it time for targeted therapy? A narrative review","volume":"61","author":"Viola","year":"2025","journal-title":"Medicina (Kaunas)"},{"issue":"6","key":"2026061619565718100_dgag037-B5","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1530\/EJE-11-0548","article-title":"Incidence of hyperthyroidism in Sweden","volume":"165","author":"Abraham-Nordling","year":"2011","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"2026061619565718100_dgag037-B6","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1210\/jc.2012-1275","article-title":"Incidence and clinical presentation of moderate to severe Graves\u2019 orbitopathy in a Danish population before and after iodine fortification of salt","volume":"97","author":"Laurberg","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2026061619565718100_dgag037-B7","doi-asserted-by":"crossref","first-page":"615993","DOI":"10.3389\/fendo.2020.615993","article-title":"Epidemiology, Natural history, risk factors, and prevention of Graves\u2019 orbitopathy","volume":"11","author":"Bartalena","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"2026061619565718100_dgag037-B8","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1210\/jc.2012-3873","article-title":"Prevalence and natural history of Graves\u2019 orbitopathy in a large series of patients with newly diagnosed graves\u2019 hyperthyroidism seen at a single center","volume":"98","author":"Tanda","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"2026061619565718100_dgag037-B9","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1136\/bjo-2022-322442","article-title":"Presentation of Graves\u2019 orbitopathy within European Group On Graves\u2019 Orbitopathy (EUGOGO) centres from 2012 to 2019 (PREGO III)","volume":"104","author":"Schuh","year":"2024","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"2026061619565718100_dgag037-B10","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1056\/NEJM199801083380201","article-title":"Relation between therapy for hyperthyroidism and the course of Graves\u2019 ophthalmopathy","volume":"338","author":"Bartalena","year":"1998","journal-title":"N Engl J Med"},{"issue":"26","key":"2026061619565718100_dgag037-B11","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1056\/NEJM199206253262603","article-title":"Occurrence of ophthalmopathy after treatment for Graves\u2019 hyperthyroidism. The Thyroid Study Group","volume":"326","author":"Tallstedt","year":"1992","journal-title":"N Engl J Med"},{"issue":"6","key":"2026061619565718100_dgag037-B12","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1111\/j.1365-2265.2008.03279.x","article-title":"Radioiodine therapy (RAI) for Graves\u2019 disease (GD) and the effect on ophthalmopathy: a systematic review","volume":"69","author":"Acharya","year":"2008","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"20","key":"2026061619565718100_dgag037-B13","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa1012985","article-title":"Selenium and the course of mild Graves\u2019 orbitopathy","volume":"364","author":"Marcocci","year":"2011","journal-title":"N Engl J Med"},{"issue":"6","key":"2026061619565718100_dgag037-B14","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1530\/EJE-18-0039","article-title":"Predictive score for the development or progression of Graves\u2019 orbitopathy in patients with newly diagnosed Graves\u2019 hyperthyroidism","volume":"178","author":"Wiersinga","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2026061619565718100_dgag037-B15","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1159\/000443828","article-title":"The 2016 European Thyroid Association\/European Group on Graves\u2019 orbitopathy guidelines for the management of Graves\u2019 orbitopathy","volume":"5","author":"Bartalena","year":"2016","journal-title":"Eur Thyroid J"},{"issue":"5","key":"2026061619565718100_dgag037-B16","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/joim.13524","article-title":"Current concepts regarding Graves\u2019 orbitopathy","volume":"292","author":"Bartalena","year":"2022","journal-title":"J Intern Med"},{"issue":"Suppl. 1","key":"2026061619565718100_dgag037-B17","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1159\/000509615","article-title":"Oxidative stress in Graves disease and graves orbitopathy","volume":"9","author":"Lanzolla","year":"2020","journal-title":"Eur Thyroid J"},{"key":"2026061619565718100_dgag037-B18","doi-asserted-by":"crossref","first-page":"608428","DOI":"10.3389\/fendo.2020.608428","article-title":"Selenium in the treatment of Graves\u2019 hyperthyroidism and eye disease","volume":"11","author":"Lanzolla","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"5","key":"2026061619565718100_dgag037-B19","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.numecd.2015.01.003","article-title":"Type 2 diabetic patients with Graves\u2019 disease have more frequent and severe Graves\u2019 orbitopathy","volume":"25","author":"Le Moli","year":"2015","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"3","key":"2026061619565718100_dgag037-B20","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1001\/jamaophthalmol.2014.5103","article-title":"Risk factors for developing thyroid-associated ophthalmopathy among individuals with Graves disease","volume":"133","author":"Stein","year":"2015","journal-title":"JAMA Ophthalmol"},{"issue":"5","key":"2026061619565718100_dgag037-B21","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1210\/clinem\/dgab070","article-title":"Statins decrease the risk of orbitopathy in newly diagnosed patients with Graves disease","volume":"106","author":"Nilsson","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2026061619565718100_dgag037-B22","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1089\/thy.2017.0430","article-title":"High serum cholesterol is a novel risk factor for Graves\u2019 orbitopathy: results of a cross-sectional study","volume":"28","author":"Sabini","year":"2018","journal-title":"Thyroid"},{"issue":"12","key":"2026061619565718100_dgag037-B23","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1007\/s40618-018-0915-z","article-title":"Relationship between serum cholesterol and Graves\u2019 orbitopathy (GO): a confirmatory study","volume":"41","author":"Lanzolla","year":"2018","journal-title":"J Endocrinol Invest"},{"issue":"11","key":"2026061619565718100_dgag037-B24","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S2213-8587(21)00238-2","article-title":"Statins for Graves\u2019 orbitopathy (STAGO): a phase 2, open-label, adaptive, single centre, randomised clinical trial","volume":"9","author":"Lanzolla","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"2026061619565718100_dgag037-B25","doi-asserted-by":"crossref","first-page":"848","DOI":"10.3390\/jpm14080848","article-title":"Subclinical ocular motility dysfunction and extraocular muscle changes in inactive Graves\u2019 orbitopathy","volume":"14","author":"Lixi","year":"2024","journal-title":"J Pers Med"},{"issue":"1","key":"2026061619565718100_dgag037-B26","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s00592-016-0909-2","article-title":"Type 1 diabetes in Sardinia: facts and hypotheses in the context of worldwide epidemiological data","volume":"54","author":"Songini","year":"2017","journal-title":"Acta Diabetol"},{"issue":"8","key":"2026061619565718100_dgag037-B27","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1007\/BF03343896","article-title":"The sardinian autoimmunity study. 4. Thyroid and islet cell autoantibodies in sardinian pregnant women at delivery: a cross-sectional study","volume":"24","author":"Olivieri","year":"2001","journal-title":"J Endocrinol Invest"},{"issue":"6","key":"2026061619565718100_dgag037-B28","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1097\/00004728-197903060-00019","article-title":"Appearance of Graves\u2019 disease on orbital computed tomography","volume":"3","author":"Enzmann","year":"1979","journal-title":"J Comput Assist Tomogr"},{"issue":"9","key":"2026061619565718100_dgag037-B29","first-page":"2830","article-title":"Untreated Graves\u2019 disease patients without clinical ophthalmopathy demonstrate a high frequency of extraocular muscle (EOM) enlargement by magnetic resonance","volume":"80","author":"Villadolid","year":"1995","journal-title":"J Clin Endocrinol Metab"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgag037\/66712753\/dgag037.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/7\/e1863\/66712753\/dgag037.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/7\/e1863\/66712753\/dgag037.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:57:08Z","timestamp":1781654228000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/111\/7\/e1863\/8455657"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,2]]},"references-count":29,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,2,2]]},"published-print":{"date-parts":[[2026,6,17]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgag037","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,2,2]]}}}